Concepedia

Jörg Schilling

JS

Statistics

Publications

5

Citations

248

H-Index

5

Active since

2014

Affiliations

Rotkreuzklinikum München(Current)

German Breast group

München Klinik Harlaching

Riemser Pharma (Germany)

University Hospital Ulm

Jörg Schilling is an author at Rotkreuzklinikum München specializing in oncology, medicine, and pharmacology.

Publications per year

2014–2022

5

Publications

5

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

, , +15

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

, , +17

Real-World Evidence of NEPA, Netupitant-Palonosetron, in Chemotherapy-Induced Nausea and Vomiting Prevention: Effects on Quality of Life

Meinolf Karthaus, Gülten Oskay-Özcelik, P Wülfing et al. · Future Oncology · 2020 · 30 citations · Full text

, , +17

Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer

Jens‐Uwe Blohmer, Theresa Link, Mattea Reinisch et al. · JAMA Oncology · 2022 · 20 citations · Full text

, , +17

Quality of Life Effects of an Oral Fixed Combination of Netupitant and Palonosetron in Chemotherapy-Induced Nausea and Vomiting Prevention: Real-World Evidence in Patients with Breast Cancer Receiving Anthracycline-Cyclophosphamide-Based Chemotherapy

Jörg Schilling, Christian M. Kurbacher, Claus Hanusch et al. · Breast Care · 2021 · 12 citations · Full text

, , +17

1–5 of 5